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Modeling biological and genetic diversity in
upper tract urothelial carcinoma with patient
derived xenografts
Kwanghee Kim 1,12, Wenhuo Hu 2,12, François Audenet 3, Nima Almassi3, Aphrothiti J. Hanrahan2,
Katie Murray 3, Aditya Bagrodia3, Nathan Wong3, Timothy N. Clinton 3, Shawn Dason3, Vishnu Mohan4,
Sylvia Jebiwott1, Karan Nagar1, Jianjiong Gao5, Alex Penson 2, Chris Hughes1, Benjamin Gordon 1,
Ziyu Chen2, Yiyu Dong2, Philip A. Watson2, Ricardo Alvim1, Arijh Elzein2, Sizhi P. Gao2, Emiliano Cocco2,
Alessandro D. Santin6, Irina Ostrovnaya7, James J. Hsieh 8, Irit Sagi4, Eugene J. Pietzak3, A. Ari Hakimi 3,
Jonathan E. Rosenberg9, Gopa Iyer 9, Herbert A. Vargas10, Maurizio Scaltriti 2, Hikmat Al-Ahmadie 11,
David B. Solit 2,5,9 ✉ & Jonathan A. Coleman3 ✉

Treatment paradigms for patients with upper tract urothelial carcinoma (UTUC) are typically
extrapolated from studies of bladder cancer despite their distinct clinical and molecular
characteristics. The advancement of UTUC research is hampered by the lack of diseasespeciﬁc models. Here, we report the establishment of patient derived xenograft (PDX) and
cell line models that reﬂect the genomic and biological heterogeneity of the human disease.
Models demonstrate high genomic concordance with the corresponding patient tumors, with
invasive tumors more likely to successfully engraft. Treatment of PDX models with chemotherapy recapitulates responses observed in patients. Analysis of a HER2 S310F-mutant
PDX suggests that an antibody drug conjugate targeting HER2 would have superior efﬁcacy
versus selective HER2 kinase inhibitors. In sum, the biological and phenotypic concordance
between patient and PDXs suggest that these models could facilitate studies of intrinsic and
acquired resistance and the development of personalized medicine strategies for UTUC
patients.
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U

pper tract urothelial carcinoma (UTUC) is a rare malignancy of the renal pelvis or ureter. Although it arises from
the same urothelium and shares similarities to urothelial
carcinoma of the bladder (UCB), UTUC has distinct molecular
characteristics that are of clinical signiﬁcance. Unlike UCB,
UTUC is a Lynch Syndrome-associated malignancy, with the
most recent study demonstrating 8.7% of UTUC patients having
a pathogenic germline mutation in a Lynch Syndrome-associated
gene1. Given the relative rarity of this cancer type, treatment
guidelines such as the recommendation for the use of neoadjuvant chemotherapy are often extrapolated from UCB studies.
Recent genomic analyses of UTUC2–5 have identiﬁed a high
incidence of potentially actionable genomic alterations including
recurrent activating mutations in receptor tyrosine kinases
(FGFR3, ERBB2), HRAS, PIK3CA and TSC1. These molecular
proﬁling studies have also, however, identiﬁed signiﬁcant genetic
diversity among UTUC patients and a large number of genomic
variants of unknown signiﬁcance6,7. Patient-derived UTUC
models would facilitate the biological characterization of these
variants of unknown signiﬁcance and could also be used as preclinical models to test novel precision therapy approaches.
Although PDX models have been developed from patients with
UCB8–10, the development of UTUC PDX models has yet to be
reported. Similarly, although there are several dozen bladder
cancer cell lines in widespread use11,12, few are of upper tract
origin. The lack of UTUC-speciﬁc cell line and animal models is
thus a major hurdle to the development of more effective treatment strategies for this disease.
Here, we report on the successful development of UTUC
models that reﬂect the genetic and biological heterogeneity of the
human disease. In a subset of PDX models, chemotherapy sensitivity mirrors the drug sensitivity observed in the patients from
which they were derived. Although HER2 alterations are common
in patients with urothelial cancer, HER2-targeted therapies have
had only modest clinical impact in this disease. We thus used a
HER2-mutant PDX/PDC model to explore the biological basis for
the limited clinical activity observed to date with HER2-directed
therapies in patients with urothelial carcinoma.
Results
Integrated genomic and transcriptomic analysis of UTUC.
With the goal of facilitating the development of personalized
therapeutic approaches for patients with UTUC, we began in
2014 offering prospective clinical tumor sequencing using the
MSK-IMPACT assay to patients with UTUC13. MSK-IMPACT is
a targeted capture-based next-generation sequencing (NGS) assay
that can detect mutations, copy number alterations and select
gene fusions in up to 468 cancer-associated genes6. To deﬁne the
frequency of potentially actionable genomic alterations in UTUC,
we analyzed 37 UTUC patients from this prospectively generated
cohort and 82 UTUC patients previously analyzed retrospectively2. In total, tumor samples from 119 UTUC patients (118
nephroureterectomy and 1 resection of metastasis) were analyzed
(Supplementary Fig. 1). Consistent with prior studies in UTUC2,3,
we observed frequent mutations in potentially actionable genes
including FGFR3 (47%), ERBB2 (9%), HRAS (12%), PIK3CA
(16%) and TSC1 (14%).
Gene expression proﬁling analyses of muscle-invasive bladder
cancers have identiﬁed basal and luminal subtypes with the basal
sub-type associated with a more aggressive disease course14,15. To
determine whether UTUC tumors can be similarly stratiﬁed, we
performed whole-transcriptome RNA sequencing (RNA-seq)
(Fig. 1a, b) on 80 of the 119 UTUC tumors for which MSKIMPACT data was available. Patient demographic and clinical
information for the RNA-seq cohort are reported in Supplementary
2

Table 1. Clustering analysis based on the BASE47 gene
classiﬁers15 found that 70 tumors (87.5%) had a luminal
phenotype and 10 (12.5%) a basal phenotype (Fig. 1b). In
addition, application of a consensus classiﬁer developed by the
Bladder Cancer Molecular Taxonomy Group16 revealed that
the majority of UTUC in the cohort were luminal–papillary
(LumP, 66 tumors, 82.5%) sub-type including all 14 of the
low-grade tumors. The remainder were classiﬁed as luminal
unstable (LumU, 7 tumors, 8.75%), luminal non-speciﬁc (LumNS,
1 tumor, 1.25%), Stroma-rich (1 tumor, 1.25%) and basal/
squamous type (Ba/Sq, 5 tumors, 6.25%). The latter had high
expression of tumor basal markers including CDH3 (Cadherin-3),
CD44 (CD44 antigen), KRT5 (Keratin, type II cytoskeletal 5),
EGFR and KRT6 (Keratin, type II cytoskeletal 6) present in 4 of 5
of the Ba/Sq-type tumors. There was no signiﬁcant sub-type
difference between high- and low-grade tumors (P = 0.5389, chisquare test).
Next, we explored differences in the frequency of common
driver mutations in UTUC tumors with basal or luminal
phenotypes as deﬁned by the BASE47 classiﬁer15. The median
tumor mutation burden was 4.21 (1.7–853.2) for the luminal and
4.56 (3.1–16.4) for the basal phenotype tumors (Fig. 1a, P = 0.89).
Somatic FGFR3 mutations, which have previously been associated
with a favorable prognostic outcome in UTUC17, were only
present in luminal subtype. Conversely, there were no signiﬁcant
differences among the two subtypes in the percentage of patients
with mutations in TP53 or other driver genes commonly present
in UTUC. Finally, using a curated knowledge base of the known
biological effects of individual mutant alleles18, we observed that
39.3% of all somatic mutations identiﬁed were variants of
unknown functional signiﬁcance (Fig. 1c).
Establishment and characterization of UTUC PDX and PDC.
With the goal of exploring the biological and clinical signiﬁcance
of individual mutational events identiﬁed in the UTUC cohort,
we leveraged our prospective clinical sequencing initiative to
develop models of UTUC that reﬂect the genomic and biological
diversity of the human disease. Surgical specimens primarily
obtained following radical nephroureterectomy (RNU) were
grafted into immunocompromised NOD scid gamma (NSG) mice
to generate patient-derived xenograft (PDX) models with a
subset also cultured in vitro to develop patient-derived cell line
(PDC) models. In total, we successfully established 17 PDX
models from 34 UTUC tumors (50% take rate). The tumor
fragments at early passages of 16 among 17 PDX models were
successfully preserved as frozen stocks for future implantation
(Supplementary Table 2) to avoid late passage failure in tumorigenicity. Six PDC models among 24 tumors (6/24: take rate 25%)
also survived beyond 10 passages (Supplementary Fig. 2).
Although not statistically signiﬁcantly different, we did observe a
trend towards PDX growth in tumors that were muscle-invasive
(≥pT2 tumor stage, P = 0.166) (Table 1). All three tumors collected from distant (UCC3 [abdominal wall] and UCC11 [liver])
or lymph node (UCC32) metastatic sites successfully engrafted.
The only tumor collected at endoscopic biopsy (UCC27) did not
engraft.
To determine whether the PDX models reﬂected the histological characteristics of the patient tumors from which they were
derived, hematoxylin and eosin (H&E) stained sections from each
were evaluated by a board-certiﬁed pathologist with expertise in
GU pathology (H.A-A.) based on the current WHO classiﬁcation
for urinary tract tumors19. This analysis demonstrated histological concordance for 16/17 tumors and their corresponding
patient-matched PDX models, as well as xenografts subsequently
derived from the PDC models (Fig. 2a and Supplementary
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Fig. 1 Integrated genomic and transcriptomic analysis of UTUC cancers. a Somatic genomic landscape of 80 UTUC tumors analyzed by MSK-IMPACT
sequencing stratiﬁed by RNA sequencing analysis into luminal-like and basal-like subtypes deﬁned using the BASE47 classiﬁer (K = 2)15, and 5 subtypes
based on a consensus molecular classiﬁcation of muscle-invasive bladder cancer16. Tumor mutation burden per megabase (Mb) is indicated in log2 scale
for each sample. b Clustering analysis of RNA-seq data from 80 UTUC tumor samples based on the BASE47 classiﬁer (basal marks shown as a turquoise
vertical bar; luminal marks shown as a salmon vertical bar). Analysis of genes expressed in cancer cells of a basal-like phenotype (KRT14, CDH3, CD44,
KRT5, EGFR, KRT6A/B) is also shown (color key on the top of b). c The number of tumors with oncogenic/likely oncogenic and variants of unknown
signiﬁcance in 17 genes frequently mutated in UTUC. Source data for a and b are provided as a Source Data ﬁle.
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Table 1 Clinico-pathological characteristics of the samples
used for UTUC PDX.
Variable

PDX growth
(N = 17)

No PDX growth
(N = 17)

Median age at surgery, 69.6 (65.7–75.7) 65.6 (60.0–75.3)
years (IQR)
Gender
Male
11 (64.7)
11 (64.7)
Female
6 (35.3)
6 (35.3)
Lynch syndrome/MSI-H
Yes
4 (23.5)
1 (5.9)
No
12 (70.6)
16 (94.1)
Not tested
1 (5.9)
0 (0)
Smoking status
Current/former
10 (58.8)
16 (94.1)
Never
7 (41.2)
1 (5.9)
Prior history of urothelial
cancer
Yes
5 (29.4)
6 (35.3)
No
12 (70.6)
11 (64.7)
Location of primary
tumor
Renal pelvis
15 (88.2)
14 (82.4)
Ureter
2 (11.8)
3 (17.6)
Specimen type
Primary
14 (82.4)
16 (94.1)
Lymph node
1 (5.9)
0 (0)
Distant metastasis
2 (11.8)
0 (0)
Endoscopic biopsy
0 (0)
1 (5.9)
Grade
Low
2 (11.8)
0 (0)
High
15 (88.2)
17 (100)
pT stage
<pT2 (non-invasive)
5 (29.4)
10 (58.8)
≥pT2 (invasive)
12 (70.6)
7 (41.2)
pN stage
pN0
10 (58.8)
13 (70.5)
pN+
5 (29.4)
2 (11.8)
pNx
2 (11.8)
2 (11.8)
Prior chemotherapy
Yes
3 (17.6)
5 (29.4)
No
14 (82.4)
12 (70.6)

P-value
0.390
1.000

0.166

0.039

1.000

1.000

0.6a

0.480

0.166

0.460

0.688

Two-sided P-values were obtained using Wilcoxon-rank sum for continuous and Fisher’s exact
test for categorical variables.
aSpecimen type was dichotomized as primary vs all others for this comparison.

Table 3). For example, squamous differentiation observed in
patient tumor UCC15 was retained in the corresponding PDX
model.
As the properties and composition of extracellular matrix
(ECM) can inﬂuence cancer cell behavior20 and as optimal
preclinical models would be enriched with ECM similar to the
original cancer tissue, we performed histological staining with
Picro Sirius red followed by two-photon microscopy-second
harmonics generation imaging21,22 on UCC36 and Masson’s
trichrome staining23, which highlights the ﬁbrous collagenous
tracts in blue on UCC36, 17 and 19. Comparison of the collagen
distribution in the tumor microenvironment of patient tumors
and the corresponding patient-matched PDX models showed that
both PDX and xenografts derived from PDC retained collagen
structure although the percentage area covered by collagen matrix
in PDX models was reduced as compared to that of the
corresponding patient tumors (Supplementary Fig. 3a, b). All
three PDX models and two PDC xenografts also retained the
structure of matching patient tumors based on the presence of a
4

ﬁbrotic capsule and the presence of collagen ﬁbers within the
body of the tumor as assessed by Masson’s trichrome staining
(Supplementary Fig. 3c).
To conﬁrm that the PDX and PDC models mirrored the
genomic alterations present in the tumors from which they were
derived, we performed targeted sequencing using the MSKIMPACT assay for all 17 tumor/PDX pairs that successfully
engrafted. Overall, the somatic mutational proﬁles of the patient
tumors and resulting PDX models were highly concordant (72.7%
concordance of known and likely oncogenic mutations). The top
recurring mutated genes found in the PDX models were TERT
(53%), FGFR3 (59%), KDM6A (24%) and TP53 (29%) (Fig. 2b).
In 29% of the PDX, we observed PDX-speciﬁc deep deletions
in CDKN2A/CDKN2B, consistent with selection for loss of
these tumor suppressor genes during the process of PDX
engraftment24.
Four of the 17 tumors that engrafted were derived from
patients with microsatellite instability high (MSI-H, MSIsensor
scores ≥10) tumors including three from patients with Lynch
Syndrome (germline mutations were present in MLH1 in UCC15
and MSH2 in UCC36, UCC34). UCC17 had loss of MSH2 and
MSH6 expression by immunohistochemistry in the absence of
germline mutations in either gene. One additional Lynch case
failed to engraft. As would be expected, all four MSI-H tumors
had a high tumor mutational burden (range: 20.3–157.2 mutation
per Mb, Fig. 2c). Mutation signature decomposition analysis25
for all four MSI-H tumor/PDX pairs revealed stable mutational
signatures across passages with the MMR/MSI and aging
signatures being most predominant (Supplementary Fig. 4).
Finally, the FGFR3 R248C hotspot mutation, which has previously
been shown to be enriched in Lynch Syndrome-associated UTUC
as compared to sporadic UTUC tumors26, was present in 3 of the
4 MSI-H tumor/patient-matched PDX pairs (UCC17, UCC36 and
UCC34). In sum, there was a high level of genomic concordance
between radical nephroureterectomy-derived tumor samples and
the corresponding PDX models (Fig. 2c) with only one PDX
model, the hypermutated UCC34 PDX, displaying <50% concordance of known or likely pathogenic mutations.
To assess the extent of genomic drift resulting from establishment of the PDX and PDC models, we performed whole-exome
sequencing (WES) on two cases (UCC03 and UCC30).
Phylogenetic analysis of the WES data provided evidence of both
linear and branched evolution in the tumors and PDX/patientderived cell lines, as demonstrated by the presence of both private
and shared mutations among samples derived from the same
patient (Fig. 2d and Supplementary Fig. 5a). Analysis of the
UCC03 samples, which were derived from resection of an
abdominal wall metastasis, demonstrated that both the cell line
(CL) and PDX (X1, X2) were more genomically related to the
metastasis than to the primary tumors (P1, P2). Mutational
signature decomposition analysis26 of the UCC03 samples
identiﬁed a predominant AID/APOBEC gene editing signature
(Signatures 2 and 13), a common ﬁnding in bladder UC27,28, in
both the tumors and the PDX models. A similar AID/APOBEC
gene editing signature (Signatures 2 and 13) was identiﬁed in the
tumor of patient UCC30, however, the AID/APOBEC(2)
signature was lost in the corresponding PDX (Fig. 2e and
Supplementary Fig. 5b).
Genomic and transcriptomic predictors of engraftment. As
only 50% of the UTUC tumors successfully propagated as PDX
models, we sought to determine whether successful engraftment
was associated with speciﬁc mutational or transcriptomic signatures. Among the top 15 most frequently altered genes in our
PDX cohort, STAG2 and ERBB2 mutations were positively and
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negatively associated with successful engraftment respectively,
although the differences were not statistically signiﬁcant, possibly
due to the small sample size (Fig. 3a).
We next compared the transcriptomic proﬁles of the patient
tumors that successfully engrafted to those that did not. In total,
RNA-seq data was available for 17 of the UTUC patient tumors
for which we attempted to establish PDX models, 8 of which
engrafted and 9 of which failed to grow as PDX. There was a
distinct gene expression pattern with 749 genes differentially
expressed (FDR < 0.05 and Log FC > 1.5) between UTUC tumors
that engrafted vs those that did not (Fig. 3b). Clustering of the
patient tumors that engrafted (PDX group) vs those that failed to

engraft (No PDX group) did not strongly correlate with luminal
or basal classiﬁcation (Fig. 1a, b) based on the BASE47
classiﬁer15. More speciﬁcally, while the PDX group had higher
expression of the basal gene set as compared to the No PDX
group (Fig. 3c), this difference was not statistically signiﬁcant.
There was also no difference in ssGSEA scores for luminal genes
between the PDX and No PDX groups. However, there was
correlation between successful engraftment and the basal/
squamous signature (P = 0.04) based on the consensus clustering
classiﬁcation16. In addition, GSEA revealed that genes in cell cycle
and DNA replication pathways including SMC1 (Structural
maintenance of chromosomes protein 1 A), MCM5 (DNA
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Fig. 3 Comparison of mutation frequencies and RNA expression proﬁles. Patient specimens that resulted in successful engraftment (PDX) vs those that
did not (No PDX) were compared. a The rates of successful engraftment differed among tumors with putative driver mutations. The number of patient
cases with mutation in the gene is shown in parenthesis. b Comparison of RNA-seq data from patient specimens that successfully engrafted (PDX, n = 8,
salmon) vs those that did not (No PDX, n = 9, turquoise). 749 genes (428 upregulated and 321 downregulated) were differentially expressed between
UTUC tumors that did and did not engraft based on the z-score of normalized gene reads from RNA-seq. c Single Sample Gene Set Enrichment Analysis
(ssGSEA) scores of basal (P = 0.19) and luminal gene sets (P = 0.41) based on the BASE47 classiﬁer and ssGSEA scores of tumor basal genes (expressed
in cancer cells of a basal-like phenotype, indicated at the bottom of Fig. 1b, P = 0.04) plotted for the patient tumors resulting in PDX (n = 8) vs No PDX
(n = 9). Error bars are mean standard error from bootstrap. The center line in the boxplots indicates the mean, the lower and upper hinges correspond to
the ﬁrst and third quartiles, the upper whisker is the maxima and the lower whisker the minima. P-value indicates two-sided two group t-test without
adjustment. d GSEA plots comparing specimen that did and did not yield PDX. Enrichment of cell cycle/DNA replication pathways was observed in the
PDX group, whereas extracellular matrix receptor interaction and focal-adhesion pathways were enriched in the No PDX group. Source data for b–d are
provided as a Source Data ﬁle.

replication licensing factor MCM5) and MCM7 (DNA replication
licensing factor MCM7) were positively enriched in the patient
tumors that successfully engrafted, suggesting that the rate of cell
proliferation is an important factor for successful PDX establishment. Extracellular Matrix (ECM) receptor interaction and
focal-adhesion pathways including FN1 (Fibronectin), THBS2
(Thrombospondin-2) and COMP (Cartilage oligomeric matrix
protein) were also positively enriched in primary tumors that
failed to produce PDX tumors, suggesting that greater dependence of tumors on microenvironmental factors may have
impeded successful engraftment in a subset of patients (Fig. 3d).

6

Chemosensitivity of patients and corresponding PDX. To evaluate whether the sensitivity of the PDX models to cytotoxic chemotherapy mirrored that of the UTUC tumors from which they
were derived, mice bearing established PDX tumors from three
patients were treated with chemotherapy regimens and dosing
schedules similar to that of the corresponding patients. As an
example, patient UCC03 developed abdominal wall, bone and
pelvic metastases 11 months after RNU for pT3bN0 disease. The
patient was treated with palliative excision of the left abdominal
wall metastasis and radiotherapy followed by gemcitabine/carboplatin (Gem/Carbo) chemotherapy. A PET-CT at 3-months follow-
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Fig. 4 Chemosensitivity of patients and corresponding PDX. Imaging of target lesions in patients before chemotherapy (pre-treatment) and at the time
speciﬁed post treatment. Tumor volumes for the corresponding PDX models were graphed as a function of days post-start of drug treatment. a UCC03:
FDG PET/CT scan after two cycles of gemcitabine/carboplatin (Gem/Carbo) chemotherapy demonstrated decreased radiopharmaceutical accumulation in
left iliac metastasis (partial response according to RECIST). Mice bearing the UCC03 PDX were randomized and treated with Gem/Carbo, gemcitabine,
carboplatin or vehicle (P = 0.0177, vehicle vs Gem/Carbo combination; P = 0.0065, vehicle vs gemcitabine; P = 0.138, vehicle vs carboplatin). b UCC19
received a combination of Gem/Carbo at recurrence followed by gemcitabine alone and demonstrates stable disease by RECIST criteria off treatment for
15 months. The corresponding PDX model was highly sensitive to Gem/Carbo (P < 0.0001). c UCC17 (MSI-H) received 4 cycles of neoadjuvant
gemcitabine/cisplatin. The patient’s radiographic response was minimal (stable disease by RECIST criteria) and there was no pathological response (pT3
disease at RNU). Minimal tumor growth inhibition was observed with Gemcitabine/Cisplatin in the corresponding PDX (P = 0.07). Two-way ANOVA test
(Prism) was used for statistical analysis without adjustment. Data are presented as mean values ± SD (standard deviation). Source data for preclinical
studies are provided as a Source Data ﬁle.

up demonstrated a partial response by RECIST criteria as well as
decreased 18F-ﬂuorodeoxyglucose (FDG) avidity within the dominant pelvic osseous metastasis. A PDX derived from the abdominal
metastasis was similarly responsive to Gem/Carbo (Fig. 4a).
Patient UCC19 underwent RNU for pT3 disease and relapsed
16 months later with retroperitoneal lymphadenopathy. The
patient responded to Gem/Carbo followed by gemcitabine
maintenance and has been off therapy with RECIST stable
disease for the past 15 months. Consistent with the patient’s
durable response to chemotherapy, a PDX generated at the time
of RNU (UCC19) demonstrated exquisite sensitivity to Gem/
Carbo (Fig. 4b). As DNA damage response (DDR) gene
alterations have been associated with sensitivity to platinumbased chemotherapy and improved survival in patients with
advanced UC patients29,30, we assessed whether there was
evidence of a likely pathogenic DDR gene alteration. Indeed,
both the primary tumor and corresponding PDX harbored a
truncating mutation in RECQL4 (F987*), a gene which has a role
in DNA repair by homologous recombination31.
Patient UCC17, who had an MSI-H tumor, received gemcitabine/
cisplatin neoadjuvant chemotherapy (NAC) to which he

demonstrated minimal decrease in size on CT from 2.8 to 2.2 cm
(stable disease by RECIST criteria) (Fig. 4c) and no pathologic
response (pT3N0 at RNU). The PDX generated from the primary
tumor was also unresponsive to gemcitabine/cisplatin (P = 0.07).
Similarly, UCC36 which was derived from a patient with an MSI-H
Lynch syndrome-associated UTUC was also resistant to gemcitabine/cisplatin (Supplementary Fig. 6). As chemoresistance has been
reported in colorectal cancer patients with MSI-H tumors32,33 and as
the MSI-H UCC17 and UCC36 models were relatively resistant to
gemcitabine/cisplatin chemotherapy, we assessed MSI status and
chemotherapy responsiveness in a surgical cohort of UTUC patients
treated with NAC. Of the 20 patients with UTUC who received
NAC before RNU, two were MSI-H (one of which was UCC17), one
was MSI-indeterminant (MSIsensor scores 3–10), and 17 were
microsatellite stable (MSS, MSIsensor scores <3). Deﬁning pathologic response as ≤pT1N034,35, we observed pathologic response in 10
of 17 MSS patients (59%) and in neither of the two MSI-H patients.
HER2-targeted therapy in HER2-mutant UTUC. Consistent
with retrospective studies, prospective genomic proﬁling of 44,183
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Fig. 5 Assessment of HER2-targeted strategies. a, b Fraction of patients with ERBB2 mutation or ampliﬁcation, respectively, in bladder, UTUC and other
common solid tumors in a prospectively sequenced cohort of 44,183 tumors. c Neratinib sensitivity of the UCC14-PDC (HER2 S310F-mutant UTUC),
MGHU3 [ERBB2 wildtype (wt) bladder cancer], CVX-4 (HER2 S310F-mutant cervical cancer) and BT-474 (ERBB2 ampliﬁed breast cancer) was determined
5 days post-neratinib treatment. The average values from three separate experiments (n = 3) for UCC14-PDC, MGHU3, and CVX-4 and 5 separate
experiments (n = 5) for BT-474 are shown. IC50s for neratinib were 508.3, 245.9, 56.8 and 0.1 nM for UCC14, MGHU3, CVX-4 and BT-474, respectively.
d Inhibition of ERK and AKT, downstream HER2 effectors by neratinib. Western blot was performed (repeated three times) on samples treated with
neratinib or vehicle for 1 h at the indicated concentrations. The samples were derived from the same experiment and the gels/blots were processed in
parallel. e Mice with established UCC14 tumors were treated with neratinib 20 mg/kg PO daily (5 days a week), DS-8201a 10 mg/kg i.v. once every
3 weeks or vehicle only as control. Mice bearing the PDX were randomly assigned to 3 cohorts (n = 8 per each group) and monitored twice a week [P =
0.0034, vehicle vs neratinib; P < 0.0001, vehicle vs DS-8201a; P < 0.0001, neratinib vs DS-8201a]. Two-way ANOVA test (Prism) was used for statistical
analysis. Data are presented as mean values ± SD. Source data for c–e are provided as a Source Data ﬁle.

tumors including 1032 bladder and 204 UTUC at our institution
using MSK-IMPACT revealed that mutations in ERBB2 (oncogenic/likely oncogenic) were more common in urothelial cancer
(UC) than in other common solid tumors (10.3% in bladder and 5.9
% in UTUC as compared to 3.2% in breast, 2.9% in endometrial,
2.6% in colorectal, and 2.4% in NSCLC) (Fig. 5a). ERBB2 ampliﬁcation was also common in bladder cancer and UTUC (6.2%: 64 of
1032 bladder tumors and 4.4% of UTUC: 9 of 204 tumors, Fig. 5b).
As HER2 is a validated drug target in breast and esophagogastric
cancers, there has been enthusiasm for targeting HER2 in patients
with UC. However, only limited efﬁcacy has been observed to date
with HER2 kinase inhibitors, such as an irreversible EGFR/HER2
kinase inhibitor, neratinib36.
Efforts to deﬁne the dependence of HER2-mutant urothelial
carcinoma cells on HER2 signaling have been hampered by the
lack of available preclinical models of HER2-mutant UC. As
genomic analysis revealed that the UCC14 patient tumor and
paired PDX harbored a hotspot mutation in ERBB2 (HER2
S310F), we sought to leverage this model to explore the biological
basis for the limited anti-tumor activity of HER2-targeted
therapies in patients with UC. We thus generated a cell line
from an early passage UCC14-PDX (UCC14-PDC) and assessed
its sensitivity to neratinib, a HER2 kinase inhibitor. Both UCC14PDC (IC50 508.3 nM) and MGHU3 (an ERBB2 wildtype bladder
cancer line, IC50 245.9 nM) were signiﬁcantly less sensitive
to neratinib as compared to CVX-437 (a HER2 S310F-mutant
cervical cancer line, IC50 56.8 nM) and BT-474 (an ERBB2
8

ampliﬁed breast cancer cell line, IC50 0.1 nM)(Fig. 5c). The
greater concentration of neratinib required to inhibit UCC14PDC cell growth as compared to other HER2 altered lines was
consistent with the higher concentration of drug needed to inhibit
activation of ERK, a downstream effector of HER2 (Fig. 5d).
Expression of phosphorylated AKT was also potently downregulated by neratinib in BT-474 and CVX-4 cells, but was
unchanged in UCC14-PDC, suggesting that AKT pathway
activation was not HER2 dependent in this UC model. Finally,
the limited sensitivity of the HER2 S310F-mutant UCC14-PDC to
HER kinase inhibition in culture was consistent with the relative
insensitivity of the UCC14-PDX to neratinib therapy in vivo
(Fig. 5e). In contrast to the lack of efﬁcacy of neratinib, DS-8201a,
a humanized HER2 antibody topoisomerase I inhibitor drug
conjugate (trastuzumab deruxtecan, Daiichi-Sankyo) recently
approved by the FDA for unresectable or metastatic HER2positive breast cancer (NCT03248492)38, signiﬁcantly inhibited
UCC14-PDX growth. These data suggest that antibody drug
conjugates targeting HER2 may be more effective than selective
HER kinase inhibitors in patients with HER2-mutant UC.
Discussion
A major hurdle to the development of personalized treatment
approaches for UTUC has been the lack of laboratory models for
biological and preclinical studies. Here, we report the development and biological and genomic characterization of PDX and
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PDC models from patients with UTUC. We ﬁnd that the PDX
and PDC models recapitulated the diverse landscape of genomic
alterations in UTUC. Furthermore, in the select cases tested, the
PDX models mirrored the sensitivity/resistance to standard
cytotoxic agents of the patients from which the PDX models were
derived.
Transcriptomic-based clustering analysis of 80 UTUC tumors
using the BASE47 gene classiﬁer15 found that the majority (70/80,
87.5%) of tumors had a luminal phenotype. Further, application
of the recently reported Bladder Cancer Molecular Taxonomy
Group consensus classiﬁer resulted in 66 of 80 tumors being
classiﬁed as luminal–papillary sub-type, including all 14 tumors
with low-grade histology (Fig. 1b)16. These data are consistent
with those of Robinson et al.5 and suggest that the
luminal–papillary sub-type is enriched in UTUC as compared to
bladder cancer where only 24% of tumors were luminal–papillary
sub-type16.
Another notable difference between urothelial carcinomas
arising in the upper tract and the bladder is the signiﬁcantly
higher incidence of microsatellite instability in renal pelvis and
ureteral tumors. It has been reported that patients with Lynch
syndrome-associated colorectal cancer have diminished response
to chemotherapy relative to patients with sporadic colorectal
cancer32. Our data suggest that a similar association between
chemotherapy sensitivity and MSI status might exist in patients
with UTUC. More speciﬁcally, we evaluated the sensitivity of two
UTUC PDX models (UCC17 and UCC36) derived from patients
with MSI-H tumors to platinum chemotherapies and gemcitabine
and found that both were relatively resistant to these cytotoxic
chemotherapies. Given recent studies suggesting that MSI may be
a predictive biomarker of response to immune checkpoint
blockade in multiple cancers39,40, these results suggest that MSI
status may be useful in assessing whether UTUC patients should
receive neoadjuvant cytotoxic chemotherapy, or, instead be
directed to immunotherapy-based clinical trials.
Despite the recent FDA-approval of erdaﬁtinib for FGFR3mutated metastatic bladder cancers41, the clinical impact of targeted therapies in UC has been limited to date. ERBB2 is altered
by ampliﬁcation and/or overexpression in various cancer types,
and antibodies that bind to the extracellular domain of HER2 are
now standard-of-care in ERBB2 ampliﬁed breast and esophagogastric cancers42,43. Our prospective clinical sequencing experience of over 44,000 patient tumors indicates that activating
ERBB2 mutations are more prevalent in both bladder and UTUC
than in other common solid tumor types (Fig. 5a). However, the
lack of ERBB2 mutant models of UTUC has been a major
impediment to the preclinical assessment of HER2-targeted
therapies for UTUC patients.
As the UCC14-PDX and patient tumor from which it was
derived harbored an activating hotspot mutation in the extracellular domain of HER2 (S310F), we leveraged this model to
explore the biological basis for the limited clinical activity of HER
kinase inhibitors observed to date in HER2-mutant UC patients.
Consistent with the poor response of HER2-mutant UC patients
to the HER kinase inhibitor neratinib as compared to HER2mutant breast and cervical cancer patients36, the HER2 S310Fmutant cell line UCC14-PDC was signiﬁcantly less sensitive to
neratinib than the HER2-ampliﬁed BT-474 breast cancer and
HER2 S310F-mutant CVX-4 cervical cancer cell lines. The relative lack of neratinib sensitivity of the UCC14 cell line was
consistent with the higher doses of neratinib required to inhibit
downstream ERK signaling in this cell line model as compared to
BT-474 and CVX-4 cells37. This result suggests that the variable
sensitivity of different tumor lineages to HER2-directed therapies
as reported in a recent basket trial36, is likely due, at least in part,
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to differences among cancers in their dependence on HER2 signaling for tumor growth and survival.
Li et al.44 recently reported that the HER2 antibody drug
conjugate ado-trastuzumab emtansine (T-DM1) has signiﬁcant
clinical activity in HER2-mutant lung cancer, even in tumors with
low HER2 expression. One hypothesis as to why HER2-mutant
tumors with low HER2 expression are sensitive to T-DM1 is that
mutation of HER2 may increase the efﬁciency of receptor internalization following antibody binding45. Consistent with this
ﬁnding, the UCC14-PDX was highly sensitive to DS-8201a, a
HER2 antibody drug conjugate, which was recently approved by
the FDA for unresectable or metastatic HER2-positive breast
cancer38. In sum, the data highlight the potential ability of PDX
models to guide the development of clinical trials for UTUC
patients and suggest that antibody drug conjugates targeting
HER2 may be more effective in UTUC patients than selective
HER2 kinase inhibitors.
A limitation of the current study is that detailed biological
characterization of the large number of variants of unknown signiﬁcance identiﬁed in the PDX models is beyond the capability of
any single laboratory. Thus, to facilitate biological discovery and the
development of novel therapies for UTUC, all genomic data from
the current work is available through cBioPortal [https://www.
cbioportal.org/study/summary?id=utuc_msk_2019; https://www.
cbioportal.org/study/summary?id=utuc_pdx_msk_2019] and all
models reported here will be provided as a resource to the broader
scientiﬁc community. In addition, the current collection of PDX
models was mostly derived from large surgical specimens. Generating PDX models from ureteroscopic biopsies in the pre-radical
nephroureterectomy setting would be of particular interest to assess
the potential beneﬁts of neoadjuvant chemotherapy for patients
with UTUC. This will be the focus of future work seeking to
leverage PDX models to inform clinical decision-making.
Methods
Specimen acquisition. From March 2014 to April 2017, tumors and matched
normal tissue from 34 patients with UTUC (31 radical nephroureterectomy [RNU]
specimens, 2 samples from distant metastasis and 1 UTUC biopsy) were collected
under protocols (NCT01775072, MSKCC IRB #89-076 and IRB #06-107) approved
by the Memorial Sloan Kettering Cancer Center (MSKCC) Institutional Review
Board. We have obtained informed consent from all participants of this study.
RNU specimens were dissected robotically in a usual manner with the hilum
stapled as late as feasible to limit ischemia time. Extraction of the specimen was
performed immediately to ensure no more than 20–30 min of surgical ischemia
time before specimen removal. The specimens were then transported directly to
pathology, tumor(s) was identiﬁed grossly by a pathologist and a fresh sample for
PDX generation was collected under sterile condition. Surgical samples were then
transported to a research laboratory in RPMI medium or PBS on ice. Time from
surgical removal of tissue in the OR to placement in medium in pathology and time
from pathology to the research laboratory was ~20–40 min and 10 min, respectively. For all specimens, representative hematoxylin and eosin (H&E) slides from
frozen tissue and formalin-ﬁxed parafﬁn-embedded (FFPE) sections were reviewed
by a board-certiﬁed genitourinary pathologist (H.A-A.) to conﬁrm histology, grade
and stage. Clinical and demographic information was obtained from a prospectively maintained institutional database.

Establishment of xenografts from surgical specimen. All animal work was
approved by the MSKCC Institutional Animal Care and Use Committee (IACUC).
We have complied with all relevant ethical regulations. All surgical specimens were
transported in RPMI medium or PBS on ice, washed with cold PBS, cut into small
pieces (2 × 2 to 3 × 3 mm3) and then implanted subcutaneously into one or two sides
of the ﬂank of 6–8-week-old male immunocompromised NOD-SCID IL2Rg−/−
(NSG) mice (Jackson Laboratory) via a 4–5 mm skin incision over the mid-lumbar
spine46,47. PDX from UCC11 was generated from a frozen cell pellet after a collagenbased digestion process. PDX were serially transplanted for expansion when the
tumor volume reached 0.5–1 cm3. Harvested xenograft tumors were cut into small
fragments as earlier and either stored in freezing media (Recovery™ Cell Culture
Freezing Medium, Thermo Fisher Scientiﬁc) in liquid nitrogen for future implantation and/or ﬂash frozen for molecular studies including RNA-seq and/or western blot
analysis.
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Primary culture and xenograft implantation. Tumor tissues were minced to
small pieces, processed using 225 U/ml Collagenase type III at 37 °C for 15–30 min
before plating into collagen-coated plates in advanced DMEM/F12 medium, supplemented with 10% FBS, 2 mM Glutamax, 1 mM sodium pyruvate, 1× nonessential amino acid, 10 mM HEPES, 100 µg/ml primocin (InVivoGen), 50 ng/ml
EGF (MilliporeSigma) and 10 µM Y-27632 (Selleck Chemicals). All cell culture
components were from Thermo Fisher Scientiﬁc unless otherwise stated. When the
plates became conﬂuent, cells were trypsinized using 0.25% TrypLE for expansion.
For generation of the UCC14 patient-derived cell line (UCC14-PDC), a PDX piece
at passage 3 was processed using 225 U/ml Collagenase type III, mixed with
Matrigel (growth factor reduced; Corning Life Sciences) at 1:1 and plated as
multiple 50 µl drops in 6-well plates to establish a 3D culture and then converted to
a cell line for growth in 2D for in vitro assays. For in vivo tumorigenesis studies of
the patient-derived cell lines shown in Supplementary Fig. 2, 3–5 million cells of
PDC in media mixed with Matrigel at 1:1 were subcutaneously injected into the
ﬂank of NSG mice and tumor growth was measured weekly by calipers.
Targeted (MSK-IMPACT) and whole-exome sequencing. Targeted sequencing
was performed using the MSK-IMPACT (Memorial Sloan Kettering Integrated
Mutation Proﬁling of Actionable Cancer Targets) assay using FFPE tumors and
matched FFPE normal tissue or frozen blood. Matched normal tissue samples
were obtained from renal parenchyma or lymph nodes that were conﬁrmed to be
histologically benign. MSK-IMPACT is a hybridization capture-based assay for
deep sequencing of cancer-associated genes. A 300 gene version was used for
the UTUC samples analyzed retrospectively, whereas 341, 410 or 468 versions
were used for the prospectively sequenced tumors and PDX and PDC models.
Brieﬂy, following DNA extraction, an equimolar pool of barcoded libraries was
subjected to exon capture using custom oligonucleotides, sequenced on an Illumina
HiSeq 2500 instrument (Illumina Inc), and analyzed using a customized pipeline
for somatic mutation calling, copy number alterations and structural
rearrangements6.
DNA samples for whole-exome sequencing were barcoded and then processed
using SureSelect Human All Exon V4 (Agilent Technologies) according to the
manufacturer’s instructions followed by sequencing on a HiSeq 2500 instrument in
100-bp paired-end mode. The average aligned reads per samples were 95 million,
with 235-fold coverage on targeted regions, and an average duplication rate of
17.6%. For phylogenetic analysis, sample distances between pairs of samples were
calculated based on non-shared mutations, followed by hierarchical clustering
using the average agglomeration method. We used the Stringlist package in R
software to count the non-shared mutations and the Analysis of Phylogenetics and
Evolution package to plot the tree. The resulting phylogenetic trees were then
denoted with notable oncogenic mutations.
RNA sequencing and transcriptome analyses. Total RNA from frozen tissue was
isolated using Trizol (Thermo Fisher Scientiﬁc) and the quantity and quality of the
resulting RNA was measured using an Agilent 2100 Bioanalyzer. The TruSeq RNA
Library Prep Kit v2 (Illumina) was used for library preparation, followed by
sequencing (60 million paired-end reads) on an Illumina HiSeq 2500. Read numbers
for genes were extracted by RSEM (using the STAR alignment program)48. Mean
aligned reads per sample was 25 million. The consensusMIBC package (https://github.
com/cit-bioinfo/consensusMIBC, Bladder Cancer Molecular Taxonomy Group)16 was
used for a consensus clustering analysis. Differentially expressed genes between the
tumors that led to PDX (PDX group) vs those that failed to produce PDX (No PDX
group) were identiﬁed by DESeq249. Gene Set Enrichment Analysis was applied to
identify pathways signiﬁcantly different in the PDX vs No PDX groups50.
Two-photon microscopy and second harmonics generation. Unstained patient,
PDX and PDC-derived FFPE tumors were cut into 15-μm-thick sections, de-parafﬁnized, hydrated and visualized using a two-photon microscope (2PM: Zeiss
LSM 880 upright Laser Scanning Microscope) with non-linear optics, coupled with
a Chameleon MPX (Coherent Inc.) femtosecond pulsed, tunable Ti: Sapphire laser
for two-photon excitation with Plan Apochromat ×20/0.8 (Carl Zeiss, Germany).
For collagen second harmonic imaging, a wavelength of 880 nm was used. Both
reﬂected and transmitted signals were collected for image analysis and processed
using Zeiss Zen imaging software.

FFPE sections were de-waxed, hydrated and a trichrome staining23 was performed
using the Masson Trichrome Staining Kit (Sigma-Aldrich, St Louis, MO, USA).
Slides were dehydrated quickly in 95% and absolute ethanol, cleared in xylene and
mounted. Slides were scanned using Pannoramic scanner (3D Histech Ltd.) and
analyzed using Pannoramic viewer (3D Histech Ltd.).
Treatment of PDX-bearing mice with chemotherapy. Chemotherapy was
administered intraperitoneally when tumor volumes reached 100–300 mm3. For
drug studies, mice were randomly assigned into vehicle control (saline for gemcitabine and platin drugs) and treatment groups (6–12 mice per each group). Mice
were treated with the combination of weekly 50 mg/kg of gemcitabine and 5 mg/kg
cisplatin (4-week cycle; weekly gemcitabine with 4th week off and cisplatin at every
4 weeks) or the combination of weekly 50 mg/kg of gemcitabine and 50 mg/kg
carboplatin (4-week cycle). Tumor growth was quantitated weekly using calipers
and growth curves were generated using GraphPad Prism software. Following
guidelines set forth by the IACUC, mice were killed when tumor volume reached
1 cm3. All drugs were purchased from Selleck Chemicals.
Neratinib and DS-8201a sensitivity assays. UCC14-PDC (ERBB2 S310F
mutated bladder cancer), BT-474 (ERBB2 ampliﬁed breast cancer), MGHU3
(ERBB2 wildtype bladder cancer, kindly provided by Dr. Margaret Knowles) and
CVX-4 (ERBB2 S310F mutated cervical cancer) cells were treated with neratinib
(Puma Biotechnology) at concentrations ranging from 0 to 1000 nM. For growth
assays, cells were seeded into 6-well plates. After allowing 24 h for adherence, cells
were then counted at Day 0 time point, or at Day 5 post treatment with neratinib or
DMSO using the Vi-CELL XR 2.03 (Beckman Coulter). Growth curves were
generated from the averages of at least 3 experiments in duplicate (±SE) by plotting
percent growth [(mean cell number at drug dose D5 − mean cell number of control
D0)/(mean cell number of DMSO D5 − mean cell number of control D0) × 100)]
against drug concentration. For in vivo drug studies, a UCC14-PDX tumor was
mechanically dissociated, resuspended in Matrigel at 1:1 and subcutaneously
injected into the ﬂanks of male NSG mice (Jackson Laboratories). Once tumors
reached an average volume of 100 mm3, mice were randomized to receive either
vehicle control (0.5% methylcellulose/0.2% Tween 80 for neratinib, PBS for DS8201a), neratinib, or DS-8201a (Daiichi-Sankyo). The dosing schedules were as
follows: neratinib at 20 mg/kg p.o. daily 5 days/week, DS-8201a at 10 mg/kg i.v.
once every 3 weeks. Tumors were measured twice a week using calipers. Interested
parties should contact Dr. Alessandro Santin for CVX-4 and Dr. Margaret Knowles
for MGHU3 cell lines.
For western blot studies, cells were seeded into 60 mm dishes. At 75%
conﬂuence in log phase growth, cells were treated with neratinib at 0–250 nM for
1 h and then lysed in 1% NP-40 lysis buffer or RIPA buffer and processed for
immunoblotting37,52. For primary antibodies, phospho-antibodies were used at
1:500 in TBST/5%BSA and totals were used at 1:1000 TBST/5% BSA with
incubation overnight at 4 °C. Secondary antibodies were used at 1:2000 TBST/5%
BSA for 1 hr at room temperature. ERK (#9102), p-ERK (T202/Y204) (#9101),
AKT (#9272) and p-AKT (Ser473) (#9271) antibodies were from Cell
Signaling Technology. Proteins were visualized using the Fuji LAS-4000 (GE
LifeSciences).
Statistical analysis. A xenograft was deemed to have successfully engrafted when
the tumor volume reached 1 cm3 or the maximum tumor diameter reached 1.5 cm,
and urothelial carcinoma was conﬁrmed by histopathology of the grafted tumors.
Clinical variables of patients and differences in engraftment rates were analyzed
using Fisher’s exact testing for categorical variables and Wilcoxon rank sum for
continuous variables. Treatment effects on tumor growth were evaluated by twoway analysis of variance (two-way ANOVA, GraphPad Prism software Version 8).
R/Bioconductor packages53 were used to analyze RNA-Seq data (DESeq2 package)
and DNA mutations (maftools package). In addition, gene set variation analysis
was performed using single sample GSEA (within GSVA package).
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.

Data availability
Picro Sirius red staining. The patient, PDX and PDC-derived tumor FFPE sections were stained with Picro Sirius red51 to quantitate changes in deposition or
architecture of extracellular matrix structures, speciﬁcally collagen ﬁbers. De-waxed
and hydrated parafﬁn sections were stained for 1 h and washed in two changes of
acidiﬁed water. Slides were dehydrated in three changes of 100% ethanol, cleared in
xylene and mounted in a resinous medium. Slides were scanned using Pannoramic
scanner (3D Histech Ltd.) and analyzed using Pannoramic viewer (3D Histech
Ltd.) and FIJI (Image J) software.
Masson’s trichrome staining. For direct visualization of collagen ﬁbers and histological assessment of collagen deposition, patient, PDX and PDC-derived tumor
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All genomic data are accessible on cBioPortal at the following two links; Upper Tract
Urothelial Carcinoma (MSK, 2019) [https://www.cbioportal.org/study/summary?
id=utuc_msk_2019] or Upper Tract Urothelial Carcinoma PDX (MSK, 2019) [https://
www.cbioportal.org/study/summary?id=utuc_pdx_msk_2019]. The raw and normalized
RNA sequencing data are available in the database of Gene Expression Omnibus (GEO)
associated with series entry number GSE134292. The source data underlying Figs. 1a, b,
2b–e, 3b–d, 4a–c, 5c–e and Supplementary Figs. 2, 4, 6 are provided as a Source Data File.
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